Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
-6.93% $3.40
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 38.71 mill |
EPS: | -1.310 |
P/E: | -2.59 |
Earnings Date: | May 13, 2024 |
SharesOutstanding: | 11.40 mill |
Avg Daily Volume: | 0.0405 mill |
RATING 2024-03-28 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Neutral | |
P/E: | Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -2.59 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.01x |
Company: PE -2.59 | industry: PE 222.16 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 2.87 - 3.93 ( +/- 15.59%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-11-22 | Winer Gary M | Buy | 300 | Common Stock |
2023-11-16 | Winer Gary M | Buy | 1 000 | Common Stock |
2023-11-15 | Winer Gary M | Buy | 500 | Common Stock |
2023-11-10 | Winer Gary M | Buy | 1 000 | Common Stock |
2023-08-11 | Winer Gary M | Buy | 705 | Common Stock |
INSIDER POWER |
---|
100.00 |
Last 94 transactions |
Buy: 2 011 316 | Sell: 8 672 727 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $3.40 (-6.93% ) |
Volume | 0.0430 mill |
Avg. Vol. | 0.0405 mill |
% of Avg. Vol | 106.26 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company was incorporated in 2004 and is headquartered in Orlando, Florida.